The World Health Organization (WHO) has produced a draft Question and Answer (Q&A) document that gives additional clarification to its 2009 guidelines for evaluating similar biotherapeutic products, particularly with respect to evaluating biosimilars of monoclonal antibodies.
The World Health Organization (WHO) has produced a draft Question and Answer (Q&A) document that gives additional clarification to its 2009 guidelines for evaluating similar biotherapeutic products, particularly with respect to evaluating biosimilars of monoclonal antibodies.
The contents of the draft document, which the WHO emphasizes must be read in the context of the guidelines, were selected on the basis of the questions most frequently asked by regulators during implementation workshops for the WHO guideline document, which seeks to provide globally acceptable principles for the licensing of follow-on biologics (except for vaccines and plasma-derived products, for which the organization provides separate recommendations and guidance). The WHO says that the guidelines can be adopted in whole or in part by any national regulatory authority worldwide.
The Q&A follows 6 broad categories: the concept for licensing similar biotherapeutic products, reference biotherapeutic products, quality, nonclinical evaluation, clinical evaluation, and pharmacovigilance. Topics addressed in the Q&A range from basic definitions of terms such as “similar biotherapeutic product” and “reference biotherapeutic product” to more technical issues, such as how many batches of a product should be tested in comparability studies, how comprehensive an evaluation of glycan structure should be, and how updates to safety information for a reference product should be handled for approved biosimilars, among others.
The WHO invites stakeholders to submit written comments on the draft to the Department of Essential Medicines and Health Products by September 20, 2018. After the organization’s Expert Committee on Biological Standardization has had the opportunity to review the comments and discuss any alterations to the document, the outcome of its deliberations will be published in the WHO Technical Report Series.
Additional initiatives of the WHO on promoting biosimilars include its pilot program to prequalify biosimilars for oncology indications. In May 2017, the organization announced that it would launch the pilot, which intended to expand access to some of the most expensive biologics in low- and middle-income countries.
Under the program, if the WHO finds that a biosimilar is comparable to its reference in terms of quality, safety, and efficacy, WHO will list the product, making it eligible for procurement by United Nations agencies. It will also allow some middle- and low-income countries that rely on WHO prequalification to make the listed biosimilar available to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.